Eptinezumab for Migraine Prevention in Patients 50 Years or Older: A Subgroup Analysis of PROMISE-1 and PROMISE-2

被引：0
|
作者：
Martin, V. [1 ]
Tassorelli, C. [2 ]
Ettrup, A. [3 ]
Hirman, J. [4 ]
Cady, R. [5 ]
机构：
[1] UC Headache & Facial Pain Ctr, Cincinnati, OH USA
[2] IRCCS C Mondino Fdn, Pavia, Italy
[3] H Lundbeck & Co AS, Copenhagen, Denmark
[4] Pacific Northwest Stat Consulting Inc, Woodinville, WA USA
[5] Lundbeck La Jolla Res Ctr, San Diego, CA USA
来源：
CEPHALALGIA | 2021年 / 41卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P0289
引用
收藏
页码：157 / 157
页数：1
相关论文
共 50 条
  • [21] Eptinezumab Demonstrated Migraine Preventive Efficacy on Day 1 After Dosing: Closed Testing Analysis From PROMISE-1 and PROMISE-2
    Dodick, D. W.
    Gottschalk, C. H.
    Tepper, S. J.
    Friedman, D., I
    Cady, R.
    Smith, J.
    Hirman, J.
    Snapinn, S.
    HEADACHE, 2020, 60 : 94 - 95
  • [22] Eptinezumab Demonstrated Migraine Preventive Efficacy on Day 1 After Dosing: Closed Testing Analysis from PROMISE-1 and PROMISE-2
    Dodick, David W.
    Gottschalk, Christopher
    Tepper, Stewart J.
    Friedman, Deborah I.
    Cady, Roger
    Smith, Jeff
    Hirman, Joe
    Snapinn, Steve
    NEUROLOGY, 2020, 94 (15)
  • [23] Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2
    Lipton, Richard B.
    Goadsby, Peter J.
    Smith, Jeff
    Schaeffler, Barbara A.
    Biondi, David M.
    Hirman, Joe
    Pederson, Susan
    Allan, Brent
    Cady, Roger
    NEUROLOGY, 2020, 94 (13) : E1365 - E1377
  • [24] Eptinezumab Reduced the Frequency of Migraine Days in Patients with Chronic Migraine and Medication-Overuse Headache: Subgroup Analysis of PROMISE-2
    Diener, H. -C.
    Marmura, M.
    Hirman, J.
    Mehta, L.
    Brevig, T.
    Brunner, E.
    Cady, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 155 - 155
  • [25] Eptinezumab Reduced the Frequency of Migraine Days in Patients With Chronic Migraine and Medication-Overuse Headache: Subgroup Analysis of PROMISE-2
    Diener, H.
    Marmura, M.
    Hirman, J.
    Mehta, L.
    Brevig, T.
    Brunner, E.
    Cady, R.
    HEADACHE, 2020, 60 : 107 - 107
  • [26] Eptinezumab Reduced Acute Medication Use in Patients with Chronic Migraine and Medication-Overuse Headache: Subgroup Analysis of PROMISE-2
    Marmura, M.
    Diener, H. -C.
    Hirman, J.
    Cady, R.
    Brevig, T.
    Brunner, E.
    Mehta, L.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 298 - 298
  • [27] Eptinezumab for migraine prevention in patients 50 years or older
    Martin, Vincent
    Tassorelli, Cristina
    Ettrup, Anders
    Hirman, Joe
    Cady, Roger
    ACTA NEUROLOGICA SCANDINAVICA, 2022, 145 (06): : 698 - 705
  • [28] Preventive Treatment With Eptinezumab in Patients With a Dual Diagnosis of Chronic Migraine and Medication- Overuse Headache: Subgroup Analysis of PROMISE-2
    Marmura, Michael J.
    Diener, Hans-Christoph
    Cowan, Robert P.
    Starling, Amaal J.
    Hirman, Joe
    Brevig, Thomas
    Cady, Roger
    NEUROLOGY, 2023, 100 (17)
  • [29] Eptinezumab Reduced Acute Medication Use in Patients With Chronic Migraine and Medication-Overuse Headache: Subgroup Analysis of PROMISE-2
    Marmura, M.
    Diener, H.
    Hirman, J.
    Cady, R.
    Brevig, T.
    Brunner, E.
    Mehta, L.
    HEADACHE, 2020, 60 : 107 - 107
  • [30] Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study
    Smith, Timothy R.
    Janelidze, Marina
    Chakhava, George
    Cady, Roger
    Hirman, Joe
    Allan, Brent
    Pederson, Susan
    Smith, Jeff
    Schaeffler, Barbara
    CLINICAL THERAPEUTICS, 2020, 42 (12) : 2254 - +
12345